AstraZeneca
Science community calls for transparency on AstraZeneca’s halted US COVID-19 vaccine trial
September 23, 2020Research and Development AstraZeneca, COVID-19, Vaccine
The halting of AstraZeneca’s COVID-19 vaccine trial around the world was cause for much initial concern over the eventual safety …
AstraZeneca and Samsung Biologics partner up in $330m manufacturing and supply deal
September 22, 2020Manufacturing and Production AstraZeneca, Samsung BioLogics, manufacturing, pharma
AstraZeneca has announced a new global manufacturing and supply partnership with Samsung Biologics, said to be worth a potential $330.8 …
AstraZeneca’s Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer
September 21, 2020Sales and Marketing AstraZeneca
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment …
AstraZeneca and Oxford Uni’s COVID-19 vaccine trial resumes following safety review
September 14, 2020Research and Development, Sales and Marketing AstraZeneca, COVID-19, Oxford University, Vaccine
After sparking a wave of concern through industry and mainstream media with the news it had halted international studies investigating …
NICE U-turns to approve AstraZeneca’s Tagrisso in two new lung cancer indications
September 11, 2020Medical Communications, Sales and Marketing AstraZeneca, NICE, Tagrisso
NICE has announced the recommendation of AstraZeneca’s Tagrisso (osimertinib) for routine use on the NHS in England and Wales in …
AstraZeneca Chief Executive says vaccine is still possible this year
September 10, 2020Research and Development AstraZeneca, Oxford Vaccine, Vaccine, coronavirus vaccine, vaccines
Pascal Soriot, Chief Executive of AstraZeneca, said that the company’s vaccine could still be available this year, despite the clinical …
AstraZeneca slams brakes on COVID-19 vaccine trial over unexplained participant illness
September 9, 2020Research and Development AstraZeneca, COVID-19, pharma
Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted …
AstraZeneca’s Farxiga combo shows promise at Phase 3 in late-stage chronic kidney disease
September 1, 2020Manufacturing and Production AstraZeneca, ESC Congress 2020, pharma
AstraZeneca took the opportunity at the digital ESC Congress 2020 over the weekend to reveal promising new Phase 3 data …
AstraZeneca scores Japanese approval for Imfinzi combo in extensive-stage small cell lung cancer
August 21, 2020Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, Japan
AstraZeneca’s Imfinzi (durvalumab) has secured approval in Japan for the treatment of extensive-stage small cell lung cancer when combined with etoposide and …
Australia signs first COVID-19 vaccine deal for 25 million doses of AstraZeneca/Oxford University candidate
August 19, 2020Research and Development AstraZeneca, Australia, COVID-19, pharma
Australia has signed its first deal to secure doses of a potential COVID-19 vaccine for its citizens, inking a partnership …
AstraZeneca seals manufacturing deal to deliver COVID-19 vaccine in China
August 7, 2020Manufacturing and Production, Medical Communications AstraZeneca, COVID-19, China, pharma
AstraZeneca has signed its first deal in China to produce and deliver its vaccine candidate against COVID-19 in the country, …
AstraZeneca’s Fasenra has strong Phase 3 showing in severe eosinophilic asthma
August 6, 2020Research and Development AstraZeneca, Fasenra, asthma
AstraZeneca took the opportunity at the American Thoracic Society 2020 Virtual International Conference to unveil positive new Phase 3b data …
Farxiga smashes all goals in Phase 3 chronic kidney disease trial, says AstraZeneca
July 28, 2020Manufacturing and Production, Research and Development AstraZeneca, farxiga
AstraZeneca has teased new data from a Phase 3 study of its sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin) in the …
AstraZeneca partners with Daichii Sankyo in potential $6bn cancer drug deal
July 27, 2020Research and Development, Sales and Marketing AstraZeneca, Daiichi Sankyo, partnership, pharma
AstraZeneca and Daiichi Sankyo have joined forces to drive the development and commercialisation of the latter’s DS-1062, a trophoblast cell-surface …
Two CHMP recommendations for AstraZeneca: Imfinzi in first-line lung cancer, Calquence in chronic lymphocytic leukaemia
July 27, 2020Sales and Marketing AstraZeneca, CHMP, Calquence, EMA, Imfinzi
AstraZeneca has secured two new recommendations for approval of its products from the European Medicines Agency’s Committee for Medicinal Products …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
